← Leaderboards
Ann-Kathrin Eisfeld
Ohio State University
$2,137,828
Attributed
$5,569,776
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.9M · FY2022–25$2M$1.5M$1M$500K$0
'22
'23
'24
'25
Funding mix
By agency
NIH$5,569,776 · 3
By mechanism
R01$5,569,776 · 3
Top collaborators
- Elaine R Mardis6 shared
- Iannis Aifantis3 shared
- H Leighton Grimes3 shared
- Alice Scott Mims3 shared
Most similar at Ohio State University
Same institution · by research overlap
- David Matthew Lucas$355,169
- Ramiro Garzon$6,835,986
- Sharyn D Baker$10,060,478
- Amanda Ewart Toland$5,719,565
- William E. Carson$27,905,247
Others in their field
Other Rising Stars on “Sampling”
- Katherine M Thibault · Battelle Memorial Institute$134,148,552
- Christina Millin · Rho Federal Systems Division, Inc.$31,828,916
- Bridget Murphy · Broad Institute, Inc.$23,600,775
- Jinsy Andrews · Columbia University Health Sciences$21,294,649
- Sabrina Paganoni · Massachusetts General Hospital$20,824,388
- Suma Babu · Massachusetts General Hospital$20,824,388
Research focus
SamplingLeukemiaResponseTranscriptome SequencingCohortCellsMolecularMutationTreatment ResponseExome SequencingMutateGeneticGenotypeGenomicsInhibitorAcute LeukemiaGenomeInsightExhibitsGene ExpressionDesignAcute Myelocytic LeukemiaBiologicalDisease Progression
Grant awards (9)
Towards an inclusive genomic risk classification for acute myeloid leukemia (AML)$652,141
R01 · FY2025 · CA · contact PI
The role of inflammation in the regulation of immune response in acute myeloid leukemia$573,470
R01 · FY2025 · CA
Towards an inclusive genomic risk classification for acute myeloid leukemia (AML)$622,018
R01 · FY2024 · CA · contact PI
Understanding Treatment Response Patterns And Therapy Resistance In IDH-Mutant AML$617,933
R01 · FY2024 · CA · contact PI
The role of inflammation in the regulation of immune response in acute myeloid leukemia$543,631
R01 · FY2024 · CA
Towards an inclusive genomic risk classification for acute myeloid leukemia (AML)$687,428
R01 · FY2023 · CA · contact PI
Understanding Treatment Response Patterns And Therapy Resistance In IDH-Mutant AML$637,871
R01 · FY2023 · CA · contact PI
The role of inflammation in the regulation of immune response in acute myeloid leukemia$570,317
R01 · FY2023 · CA
Understanding Treatment Response Patterns And Therapy Resistance In IDH-Mutant AML$664,967
R01 · FY2022 · CA · contact PI